Review of Chinese clinical trials on CIK cell treatment for malignancies.
China is the country where the most clinical trials on CIK cells have been performed. We aimed to provide definite evidence for using CIK cell treatment and extrapolate a common applicative standard for malignancies. We chose the VIP database of Chinese scientific and technological journals to search the literature. We entered the keywords "CIK" or "xi bao yin zi you dao de sha shang xi bao" (the equivalent Chinese phrase for CIK cells, by Chinese characters) and searched for in vivo human trials. In 24 collected trials, 936 patients were treated with CIK cells, 525 men and 246 women. The cultivation time of CIK cells ranged from 7 to 28 days. In five studies, CIK cells were co-cultured with dendritic cells. The total number of CIK cells used ranged from 6×10(6) to 1.5×10(10). The total number of DC-CIK cells used ranged from 1×10(9) to 1.3×10(10). In all studies, those immune parameters and tumour markers examined increased, but not all increased significantly. Of the reported 563 patients, 40 had a complete response, 126 had a partial response, 125 had a minimal response, 135 had stable disease and 58 had progressive disease. The remaining 76 patients did not reach an objective response. The total response rate was 51.7% (291/563). The toxicities were slight. CIK cell treatment is a promising and safe modality for treating malignancies. We proposed a standard for cultivating CIK cells.
Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou 213003, People's Republic of China.
Xiao-Dong
XD
Li
Bin
B
Xu
Jun
J
Wu
Mei
M
Ji
Bei-Hua
BH
Xu
Jing-Ting
JT
Jiang
Chang-Ping
CP
Wu
D002681:China; D002986:Clinical Trials as Topic; D055612:Cytokine-Induced Killer Cells / Q000166:cytology / Q000637:transplantation*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*